Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Paxil, AstraZeneca Prilosec Have New "Product By Process" Patents

Executive Summary

GlaxoSmithKline's most recent Paxil patent illustrates the latest wrinkle in patent infringement defense: "product by process" patents, attorney Robert Green (Leydig, Voit & Mayer, Chicago) told the National Association of Pharmaceutical Manufacturers bulk workshop March 20 in New York City.
Advertisement

Related Content

FTC Asks FDA To Clarify "Orange Book" Listing Criteria In Citizen Petition
FTC Asks FDA To Clarify "Orange Book" Listing Criteria In Citizen Petition
McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
General Motors Meets With Pharma Companies To Discuss Rx Pricing, DTC
AstraZeneca Awaits "Orange Book" Listing For Three Prilosec Patents
AstraZeneca Nexium Relying On Healing Rate, Symptom Maintenance
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
Waxman/Hatch Reform Should Clarify Rules, Not Change System - Merck
Advertisement
UsernamePublicRestriction

Register

PS037551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel